KRAS and pancreatic neoplasm: Moreover, we recently demonstrated that OBP-301 and p53-armed OBP-702 exhibit high antitumor efficacy against KRAS-mutant human pancreatic cancer cells via the KRAS-MEK-ERK signaling pathway [16].